Syndrome News and Research

RSS

Capsules with essential oils reduce symptoms of premenstrual syndrome: Study

A pill containing a mix of essential oils has been shown to significantly reduce the symptoms of premenstrual syndrome. Researchers writing in BioMed Central's open access journal Reproductive Health tested the tablets by carrying out a randomised, controlled trial in 120 women.

16 Jan 2011

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

Metabolomic biomarker research is a young research area that carries great hopes for both medicine and the nutritional sciences, particularly for the early detection of genetically determined diseases.

14 Jan 2011

Merck announces changes in vorapaxar clinical studies

Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.

14 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

BMJ publishes clinical study of noninvasive, plasma DNA-based approach for prenatally detecting Down's syndrome

Sequenom is very pleased to note the publication in the British Medical Journal of a groundbreaking international study led by our longstanding collaborator, Professor Dennis Lo of The Chinese University of Hong Kong.

13 Jan 2011

Brain cell destroying genetic mechanism responsible for development of AD

Researchers at the University of British Columbia and Vancouver Coastal Health Research Institute have discovered that the genetic mechanism which destroys brain cells is responsible for early development of Alzheimer's Disease in people with Down Syndrome and for development of Alzheimer's Disease in general population - providing a potential new target for drugs that could forestall dementia in people with either condition.

13 Jan 2011

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

Some disorders of the brain are obvious - the massive death of brain cells after a stroke, the explosion in the growth of cells that marks a tumor. Other disorders, such as autism, schizophrenia and mental retardation show no physical signs of damage and are believed to be caused by problems in how brain cells communicate with one another.

13 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

Scientist develops FMR1 genetic blood test for predicting IVF outcomes

A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.

13 Jan 2011

New Down syndrome non-invasive test for ‘mums-to-be’ on the horizon

According to experts a simple DNA test for Down syndrome could save nearly all pregnant women from invasive tests like amniocentesis. Usually 3% to 5% of pregnant women in the UK or some 30,000 women have to undergo invasive tests like amniocentesis that increases the risk of miscarriage to 1%. The new DNA blood test could bring this down to 0.1%, according to a study in the British Medical Journal.

12 Jan 2011

DNA blood test can help rule out Down's syndrome among high risk pregnancies

The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the foetus has Down's.

12 Jan 2011

Eric Lancaster receives NORD grant to study stiff-person syndrome

The National Organization for Rare Disorders has awarded a research grant for the study of stiff-person syndrome, a rare acquired neurological disorder, to Eric Lancaster, MD, PhD of the University of Pennsylvania.

11 Jan 2011

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents and the accompanying requirement of long-term dual antiplatelet therapy showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention.

11 Jan 2011

Novel scoring system identifies PTEN genetic mutation

Researchers have discovered a method for more precise identification of individuals who should undergo testing for genetic mutations of the tumor suppressor gene PTEN, which associates with a variety of conditions including several types of cancers. The research has created a diagnostic scoring system that improves on established criteria.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

11 Jan 2011

Amount of alcohol and pattern of consumption affect risk of cognitive impairment

Previous research regarding the association between alcohol consumption and dementia or cognitive impairment in later life suggests that mild to moderate alcohol consumption might be protective of dementia. However, most of the research has been conducted on subjects already rather elderly at the start of the follow-up. A new study published in the December issue of the Journal of Alzheimer's Disease addresses this problem with a follow-up of more than two decades.

11 Jan 2011

Lineagen introduces FirstStep integrated genetic testing for early diagnostic evaluation of ASD, DD

Lineagen announces the launch of its FirstStep integrated genetic testing and counseling service to assist pediatricians and family physicians with the earlier, more accurate diagnostic evaluation of autism spectrum disorders and developmental delay.

11 Jan 2011

New, paid prescriptions for Questcor's Acthar increase 66%

Questcor Pharmaceuticals, Inc. today reported a strong finish to 2010. The Company estimates that 353 new, paid Acthar prescriptions for the treatment of multiple sclerosis (MS) were filled and shipped during the quarter, up 66% from the year ago period and up 9% from the third quarter of 2010.

10 Jan 2011

Miracor’s PICSO System may help advance heart failure treatment

Miracor Medical Systems GmbH announced today that its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System, designed to improve outcomes for acute coronary syndrome (ACS) and heart failure patients, has been cited as a technology that "may advance heart failure (HF) treatment significantly".

10 Jan 2011